Johnson & Johnson Innovation has launched the Asia Pacific Innovation Center in Shanghai, China, with satellites in Singapore, Australia and Japan.

The new centre will boost Johnson & Johnson Innovation Centers network in worldwide life sciences hotspots, and will feature local science and technology experts, and deal-making capabilities.

Asia Pacific Innovation Center head Dong Wu said: "The Asia Pacific Innovation Center plans to build on the company’s track record of collaboration in the region and advance the most promising science.

"It will play a key role in sourcing early stage science in the region for the development of new medicines, medical devices, and consumer products."

"The new centre will identify and develop early stage opportunities across pharmaceuticals, medical devices and diagnostics, and consumer healthcare products."

The new centre will also identify and develop early stage opportunities across three areas including pharmaceuticals, medical devices and diagnostics, and consumer healthcare products.

Johnson & Johnson China chairman Jesse Wu said: "The Asia Pacific Innovation Center supports our larger goal to address China’s specific healthcare needs, invest in local capabilities, and increase our external collaborations."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Additionally, Johnson & Johnson Innovation and Janssen-Cilag have partnered with James Cook University in Australia to enhance the hookworms ability to regulate the human immune response, allowing their survival in a human host for the benefit of people suffering with Crohn’s disease and ulcerative colitis.

Janssen Australia and Johnson & Johnson Innovation extended an existing collaboration with the University of Queensland (UoQ) to determine peptides as potential treatments for pain, and develop a more targeted approach to pain management.

A broad collaboration was also launched by Johnson & Johnson Innovation with China Pharmaceutical University on several projects across its consumer and pharmaceutical businesses.

Janssen research and development (R&D) and Johnson & Johnson Innovation launched a R&D collaboration with Peking University to determine agonists and antagonists for G protein-coupled receptors (GPCRs) to help develop novel CNS medicines.

Johnson & Johnson Innovation and Janssen R&D teamed up with Zhejiang University to clarify the physiological and pathological role of human lactate receptor GPR81 in the regulation of metabolism and metabolic syndrome.

The new Asia Pacific Innovation Center will launch a regular presence in the Suzhou BioBay incubator with more than 400 companies in the areas of drug discovery, biotech, in vitro diagnostic (IVD) medical devices and nanotech.